Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

85.84EUR
11:35am EDT
Change (% chg)

€-0.04 (-0.05%)
Prev Close
€85.88
Open
€85.94
Day's High
€86.78
Day's Low
€85.72
Volume
461,045
Avg. Vol
578,534
52-wk High
€101.55
52-wk Low
€74.54

Latest Key Developments (Source: Significant Developments)

Merck KGaA Gets First Approval For Cladribine Tablets In Middle East & Africa
Monday, 9 Apr 2018 05:25am EDT 

April 9 (Reuters) - Merck KGaA ::RECEIVES FIRST APPROVAL FOR CLADRIBINE TABLETS IN MIDDLE EAST & AFRICA REGION.  Full Article

Merck Receives Fast-Track Designation For Tepotinib In Non-Small Cell Lung Cancer In Japan
Tuesday, 27 Mar 2018 08:41am EDT 

March 27 (Reuters) - Merck KGaA ::MERCK RECEIVES FAST-TRACK DESIGNATION FOR TEPOTINIB IN NON-SMALL CELL LUNG CANCER IN JAPAN.MERCK KGAA - SAKIGAKE DESIGNATION ENCOMPASSES POSSIBILITY FOR A TARGET REVIEW PERIOD OF 6 MONTHS.MERCK KGAA - JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS SAKIGAKE DESIGNATION FOR TEPOTINIB.  Full Article

Merck KGaA Announces Positive Phase IIb Results For Evobrutinib In Relapsing Multiple Sclerosis
Wednesday, 7 Mar 2018 09:56am EST 

March 7 (Reuters) - Merck KGaA ::MERCK KGAA, DARMSTADT, GERMANY, ANNOUNCES POSITIVE PHASE IIB RESULTS FOR EVOBRUTINIB IN RELAPSING MULTIPLE SCLEROSIS.MERCK KGAA - STUDY HAS MET ITS PRIMARY ENDPOINT.  Full Article

Merck KGaA Says Cladribine Tablets Win First Approval In Latin America‍​
Monday, 26 Feb 2018 11:09am EST 

Feb 26 (Reuters) - Merck KGaA ::SAYS MAVENCLAD (CLADRIBINE TABLETS) RECEIVES FIRST APPROVAL IN LATIN AMERICA‍​.ARGENTINA'S ANMAT HAS APPROVED REGISTRATION OF CLADRIBINE TABLETS FOR THE TREATMENT OF ADULT PATIENTS WITH HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS.  Full Article

Merck KGaA Invests Additional $47 Mln To Enhance Manufacturing And Distribution In Asia
Wednesday, 21 Feb 2018 08:03am EST 

Feb 21 (Reuters) - MERCK KGAA ::MERCK KGAA, DARMSTADT, GERMANY INVESTS ADDITIONAL $47 MILLION TO ENHANCE MANUFACTURING AND DISTRIBUTION IN ASIA.BUILDS CAPABILITIES WITH TWO NEW MANUFACTURING AND DISTRIBUTION CENTERS IN SOUTH KOREA AND INDIA.  Full Article

Nestle declines to comment on interest in Pfizer, Merck units
Thursday, 15 Feb 2018 04:48am EST 

Feb 15 (Reuters) - Nestle Sa ::CEO SAYS NO COMMENT ON INTEREST IN PFIZER, MERCK CONSUMER HEALTH UNITS, BUT IS GENERALLY INTERESTED IN EXPANDING ITS CONSUMER HEALTH BUSINESS.ZONE AMERICAS HEAD SAYS EXPECTS TO SEE LIMITED PRICE INCREASES IN THE U.S. THIS YEAR, COUNTS ON VOLUME GROWTH TO DRIVE IMPROVEMENT IN ORGANIC GROWTH.  Full Article

Pangaea Oncology Signs Contract For Genetic Analysis With German's Merck
Thursday, 15 Feb 2018 03:58am EST 

Feb 15 (Reuters) - PANGAEA ONCOLOGY SA ::SIGNS CONTRACT FOR GENETIC ANALYSIS WITH GERMAN'S MERCK KGAA FOR 0.3 MILLION EUROS.THE TERM OF THE CONTRACT IS BETWEEN 12 AND 24 MONTHS.  Full Article

Forty Seven Says Agreement With Merck KGAA To Conduct Clinical Trials For Patients With Ovarian Cancer
Thursday, 11 Jan 2018 07:30am EST 

Jan 11 (Reuters) - Merck KGAA ::FORTY SEVEN - AGREEMENT WITH MERCK KGAA TO CONDUCT PHASE 1B CLINICAL TRIAL COMBINING HU5F9-G4 WITH AVELUMAB IN PATIENTS WITH OVARIAN CANCER.  Full Article

Juniper Pharmaceuticals Announces ‍Extension Of Supply Agreement For Crinone
Monday, 8 Jan 2018 07:00am EST 

Jan 8 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS ANNOUNCES 4.5-YEAR EXTENSION THROUGH 2024 OF CRINONE® SUPPLY AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY.JUNIPER PHARMACEUTICALS INC - ‍EXTENSION OF SUPPLY AGREEMENT FOR CRINONE WITH AFFILIATE OF MERCK KGAA.JUNIPER PHARMACEUTICALS INC - ‍AMENDED AGREEMENT EXTENDS SUPPLY TERM AN ADDITIONAL 4.5 YEARS AND AT LEAST THROUGH TO DECEMBER 31, 2024​.  Full Article

Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio Progress
Tuesday, 2 Jan 2018 04:05pm EST 

Jan 2 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS OUTLINES STRATEGIC PRIORITIES FOR 2018 AND REPORTS RECENT PORTFOLIO PROGRESS.JUNIPER PHARMACEUTICALS INC - ON TRACK TO BE CASH FLOW POSITIVE IN 2018.JUNIPER PHARMACEUTICALS INC - CONTINUED "STRONG" DOUBLE-DIGIT REVENUE GROWTH FOR CRINONE AND JPS EXPECTED IN 2018.JUNIPER - ACTIVE DISCUSSIONS WITH MERCK KGAA TO EXTEND CRINONE PROGESTERONE GEL AGREEMENT ARE PROGRESSING.JUNIPER PHARMACEUTICALS INC - PARTNERING OPPORTUNITIES ARE BEING "EXPLORED" FOR JNP-0101, THE OXYBUTYNIN IVR FOR TREATMENT OF OVERACTIVE BLADDER.JUNIPER PHARMACEUTICALS - PARTNERING OPPORTUNITIES ARE BEING "EXPLORED" FOR JNP-0301, A NATURAL PROGESTERONE IVR FOR PREVENTION OF PRE-TERM BIRTH.  Full Article

UPDATE 1-Germany's Merck sees performance materials unit turning corner in 2020

* Decline in liquid crystals to be offset by other business (Adds sales target for unit, divisional CEO comment)